| Literature DB >> 36134941 |
Alina Robu1, Aurora Antoniac1, Robert Ciocoiu1, Elena Grosu1, Julietta V Rau2,3, Marco Fosca2, Ivan I Krasnyuk3, Gratiela Gradisteanu Pircalabioru4,5, Veronica Manescu Paltanea1,6, Iulian Antoniac1,5, Sebastian Gradinaru7.
Abstract
The main problems directly linked with the use of PMMA bone cements in orthopedic surgery are the improper mechanical bond between cement and bone and the absence of antimicrobial properties. Recently, more research has been devoted to new bone cement with antimicrobial properties using mainly antibiotics or other innovative materials with antimicrobial properties. In this paper, we developed modified PMMA bone cement with antimicrobial properties proposing some experimental antimicrobial agents consisting of silver nanoparticles incorporated in ceramic glass and hydroxyapatite impregnated with peppermint oil. The impact of the addition of antimicrobial agents on the structure, mechanical properties, and biocompatibility of new PMMA bone cements was quantified. It has been shown that the addition of antimicrobial agents improves the flexural strength of the traditional PMMA bone cement, while the yield strength values show a decrease, most likely because this agent acts as a discontinuity inside the material rather than as a reinforcing agent. In the case of all samples, the addition of antimicrobial agents had no significant influence on the thermal stability. The new PMMA bone cement showed good biocompatibility and the possibility of osteoblast proliferation (MTT test) along with a low level of cytotoxicity (LDH test).Entities:
Keywords: TGA; antimicrobial agents; biocompatibility; bone cements; mechanical properties
Year: 2022 PMID: 36134941 PMCID: PMC9496347 DOI: 10.3390/biomimetics7030137
Source DB: PubMed Journal: Biomimetics (Basel) ISSN: 2313-7673
Composition of the new antimicrobial bone cements.
| Samples | Components | Antimicrobial Additive |
|---|---|---|
| R | Powder 40 g (87.6% PMMA, 2.4% BPO, 10% BaSO4) + Liquid 14.4 g (85.3% MMA, 13.2% BMA, 1.5% DmpT, 20 ppm HQ) | None |
| GM | 5% gentamicin—refers to the total powder weight | |
| HUM | 5% peppermint essential oil incorporated in hydroxyapatite (HAp)—refers to the total powder weight | |
| AM1 | 2% silver nanoparticles incorporated in a ceramic glass—refers to the total powder weight | |
| AM2 | 4% silver nanoparticles incorporated in a ceramic glass—refers to the total powder weight |
Methyl methacrylate—MMA; Butyl methacrylate—BMA; N,N-Dimethyl-p-toluidine—DmpT; Hydroquinone—HQ; Poly(methyl-methacrylate)—PMMA, Benzoyl peroxide—BPO, Barium sulfate—BaSO4; Hydroxyapatite—HAp.
Figure 1EDXRD spectra collected on 5 different composite samples made of PMMA-BaSO4-BPO as major components. Most intense Bragg reflections, all belonging to the PMMA component, have been labeled with the proper Miller indexes. Fluorescence contributions of Ba are visible in correspondence of the region within 30 to 40°.
EDXRD deconvoluted peaks of samples R, GH, HUM, AM1, AM2 [46].
| Peak Position (°) | Assignment | Relative Intensity | Component |
|---|---|---|---|
| 22.8 | [111] | 52% | BaSO4 |
| 25.8 | [210] | 100% | BaSO4 |
| 26.9 | [102] | 70% | BaSO4 |
| 28.7 | [211] | 99% | BaSO4 |
| 31.5 | [112] | 50% | BaSO4 |
Figure 2Raman patterns collected from 5 different composite samples made of PMMA−BaSO4 −BPO as major components. Most intense bands have been labeled and assigned to their respective component of the composite.
Attribution of Raman shifts identified in experimental bone cements.
| Raman Shift (cm−1) | Assignment | Component |
|---|---|---|
| 463 | M–O12 | BaSO4 |
| 487 | Out of plane deformation | PMMA |
| 603 | Deformation O–C=O | PMMA |
| 812 | Symmetric stretching | PMMA |
| 990 | ν1 (SO4) | BaSO4 |
| 1000 | C6H6 breathing | BPO |
| 1450 | CH2 Deformation | PMMA |
| 1730 | Stretching C=O | PMMA |
Figure 3TGA (a) and DTG (b) curves of reference R and experimental bone cement.
TGA analysis of investigated bone cement.
| Sample | Inflection Temperature at the Highest Rate of Weight Loss (°C) | Mass Loss at Inflection Temperature (%) | T10 (°C) | T50 (°C) | Residue Content at 600 °C (%) |
|---|---|---|---|---|---|
| R | 380.03 | 39.17 | 292.83 | 372.28 | 6.41 |
| AM1 | 383.14 | 36.91 | 291.65 | 373.86 | 6.0 |
| AM2 | 382.68 | 44.83 | 294.51 | 378.12 | 18.92 |
| HUM | 383.71 | 40.92 | 285.53 | 376.96 | 10.93 |
| GH | 384.41 | 40.86 | 299.46 | 377.02 | 14.54 |
Figure 4Selection of representative stress–strain curves in flexure.
Figure 5The average value of the elastic modulus in flexure for the tested samples.
The elastic modulus in flexure and flexural strength results of the experimental bone cement.
| Samples | Elastic Modulus in Flexure [GPa] | Flexural Strength [MPa] |
|---|---|---|
| R | 3.94 ± 0.15 | 56.83 ± 6.36 |
| AM1 | 4.30 ± 0.17 | 65.03 ± 9.09 |
| AM2 | 3.94 ± 0.18 | 65.46 ± 3.69 |
| HUM | 3.60 ± 0.15 | 64.44 ± 4.92 |
| GH | 3.42 ± 0.67 | 61.01 ± 7.04 |
Figure 6The average value of the flexural strength for the tested samples.
Figure 7Selection of stress-strain curves in compression from the tested samples.
Figure 8The average value of the elastic modulus in compression.
The elastic modulus in compression and yield strength results of the experimental bone cement.
| Samples | Elastic Modulus in Compression [GPa] | Yield Strength [MPa] |
|---|---|---|
| R | 2.90 ± 0.07 | 94.60 ± 4.34 |
| AM1 | 2.78 ± 0.06 | 87.40 ± 4.56 |
| AM2 | 2.74 ± 0.05 | 86.40 ± 3.29 |
| HUM | 2.64 ± 0.08 | 84.40 ± 5.86 |
| GH | 2.90 ± 0.06 | 83.40 ± 4.83 |
Figure 9The average value of the yield strength.
Figure 10Biocompatibility analysis of tested bone cement. (a) Viability and proliferation potential of the samples (Statistical significance: * p < 0.05; ** p < 0.005). (b) Cytotoxic response of the G292 osteoblasts in the presence of the samples (Statistical significance: *** p < 0.001); n = 3.
Figure 11Cell morphology in the presence of the investigated samples, phase-contrast microscopy, 10× magnification.